IMR Press / CEOG / Special Issues / ovarian_cancer

Treatment and Prognosis of Ovarian Cancer

Submission deadline: 30 June 2022
Special Issue Editors
  • Anna Myriam Perrone, MD
    Division of Oncologic Gynecology, IRCCS-Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy,University of Bologna, Bologna, Italy
    Interests: surgery; intraperitoneal chemotherapy; fertility sparing; rare oncological diseases of the uterus
  • Pierandrea De Iaco, MD
    Division of Oncologic Gynecology, IRCCS-Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; University of Bologna, Bologna, Italy
    Interests: surgery; intraperitoneal chemotherapy; fertility sparing; rare oncological diseases of the uterus
Special Issue Information

Dear Colleagues,

Although rare, ovarian cancer is one of the deadliest gynaecological cancers. In most cases it is detected as an advanced tumor, since early diagnosis is not possible for most forms of the disease. Surgery and platinum-based compounds have been the mainstay of therapy for many years. The prognosis for ovarian cancer depends on the type of surgery and on the response to chemotherapy. Other regimens have little effect if the disease does not respond to platinum. Platinum has been the most common treatment for many years, even though several new therapies are emerging. The role of the BRCA test in deciding whether or not to administer PARP-inhibitors is now becoming increasingly important.

In this collection of articles, we would like to evaluate the efficacy of new medical and surgical therapies in relation to the patient’s BRCA mutational status. This will provide an overview of recent attempts to improve the diagnosis and prognosis of ovarian cancer.

We are particularly interested in new diagnostic and therapeutic strategies or literature reviews that lay out the foundation for these improvements.

Dr.  Anna Myriam Perrone and Dr. Pierandrea De Iaco

Guest Editors

Keywords
ovarian cancer
chemotherapy
surgery
parp-inhibitors
immunotherapy
epithelial forms
platinum compounds
chemoresistance
palliative care
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (2 Papers)
Back to top